Motco lessened its stake in Baxter International Inc (NYSE:BAX) by 38.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 547 shares of the medical instruments supplier’s stock after selling 345 shares during the period. Motco’s holdings in Baxter International were worth $46,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of BAX. State Street Corp grew its stake in shares of Baxter International by 2.6% in the third quarter. State Street Corp now owns 24,189,517 shares of the medical instruments supplier’s stock worth $2,120,911,000 after acquiring an additional 620,579 shares in the last quarter. BlackRock Inc. grew its stake in shares of Baxter International by 1.4% in the second quarter. BlackRock Inc. now owns 40,589,288 shares of the medical instruments supplier’s stock worth $3,324,263,000 after acquiring an additional 560,814 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Baxter International by 43.3% in the fourth quarter. New York State Common Retirement Fund now owns 1,767,166 shares of the medical instruments supplier’s stock worth $147,770,000 after acquiring an additional 534,256 shares in the last quarter. PGGM Investments acquired a new position in shares of Baxter International in the fourth quarter worth $37,322,000. Finally, Anchor Capital Advisors LLC grew its stake in shares of Baxter International by 102.4% in the fourth quarter. Anchor Capital Advisors LLC now owns 542,346 shares of the medical instruments supplier’s stock worth $45,351,000 after acquiring an additional 274,388 shares in the last quarter. Institutional investors and hedge funds own 82.61% of the company’s stock.
BAX has been the subject of several research reports. UBS Group restated a “buy” rating and issued a $102.00 price target on shares of Baxter International in a research note on Monday, January 13th. Goldman Sachs Group initiated coverage on shares of Baxter International in a research note on Wednesday. They issued a “buy” rating and a $104.00 price target for the company. Wells Fargo & Co boosted their price target on shares of Baxter International from $100.00 to $102.00 and gave the stock an “overweight” rating in a research note on Friday. Evercore ISI upgraded shares of Baxter International from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $80.00 to $94.00 in a research note on Thursday, January 2nd. Finally, Deutsche Bank initiated coverage on shares of Baxter International in a research note on Monday, October 21st. They issued a “buy” rating and a $109.00 price target for the company. Six research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $93.50.
In other news, Director John D. Forsyth sold 1,500 shares of Baxter International stock in a transaction on Friday, December 13th. The shares were sold at an average price of $83.64, for a total transaction of $125,460.00. Following the completion of the sale, the director now directly owns 30,078 shares of the company’s stock, valued at approximately $2,515,723.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.70% of the stock is currently owned by insiders.
Baxter International stock opened at $93.14 on Friday. The stock has a market cap of $47.26 billion, a P/E ratio of 28.66, a price-to-earnings-growth ratio of 2.16 and a beta of 0.96. The company has a fifty day simple moving average of $88.60 and a 200-day simple moving average of $85.45. Baxter International Inc has a 12-month low of $72.42 and a 12-month high of $95.00. The company has a current ratio of 2.78, a quick ratio of 2.10 and a debt-to-equity ratio of 0.72.
Baxter International Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: How to build a Fibonacci channel
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.